A randomized trial of ascorbic acid for the prevention of post-reperfusion syndrome during liver transplantation.

ABSTRACT:

Background

Post-reperfusion syndrome (PRS) is a critical hemodynamic complication during liver transplantation, characterized by a significant drop in mean arterial pressure and associated with increased morbidity and mortality, systemic inflammation, and ischemia-reperfusion injury. Ascorbic acid (AA), with its antioxidant and anti-inflammatory properties, has been proposed as a potential therapeutic intervention.

Methods

A single-center, double-blind, randomized controlled trial was conducted at the Hospital Universitario Ramón y Cajal, Madrid. Patients undergoing liver transplantation were randomly assigned to receive either 1500 mg of intravenous AA during the anhepatic phase (vitamin C-treated group) or 0.9% saline as a placebo (control group). The primary endpoint was

SUBMITTER: Gajate Martin L 

PROVIDER: S-EPMC12306706 | biostudies-literature | 2025 Aug

REPOSITORIES: biostudies-literature